Takeru Nose

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2285019/publications.pdf

Version: 2024-02-01

63	840	586496	651938
papers	citations	16	25
		h-index	g-index

64	64	64	818
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metal ion scavenging activity of elastin-like peptide analogues containing a cadmium ion binding sequence. Scientific Reports, 2022, 12, 1861.	1.6	2
2	Flexible customization of the selfâ€assembling abilities of short elastinâ€like peptide Fn analogs by substituting Nâ€terminal amino acids. Biopolymers, 2022, 113, .	1.2	5
3	Bisphenol-C is the strongest bifunctional ERÎ±-agonist and ERÎ²-antagonist due to magnified halogen bonding. PLoS ONE, 2021, 16, e0246583.	1.1	7
4	Simple Regulation of the Self-Assembling Ability by Multimerization of Elastin-Derived Peptide (FPGVG)_n Using Nitrilotriacetic Acid as a Building Block. ACS Omega, 2021, 6, 5705-5716.	1.6	7
5	Bisphenol A derivatives act as novel coactivator-binding inhibitors for estrogen receptor Î². Journal of Biological Chemistry, 2021, 297, 101173.	1.6	15
6	Direct evidence of edge-to-face CH/Ï€ interaction for PAR-1 thrombin receptor activation. Bioorganic and Medicinal Chemistry, 2021, 51, 116498.	1.4	4
7	Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126815.	1.0	1
8	Bisphenol AF: Halogen bonding effect is a major driving force for the dual ERÎ±-agonist and ERÎ²-antagonist activities. Bioorganic and Medicinal Chemistry, 2020, 28, 115274.	1.4	15
9	Mechanistic Insights into a DMSO-Perturbing Inhibitory Assay of Hyaluronidase. Biochemistry, 2020, 59, 3879-3888.	1.2	0
10	Evaluation of the Influence of Halogenation on the Binding of Bisphenol A to the Estrogen-Related Receptor Î³. Chemical Research in Toxicology, 2020, 33, 889-902.	1.7	6
11	Receptor-binding affinities of bisphenol A and its next-generation analogs for human nuclear receptors. Toxicology and Applied Pharmacology, 2019, 377, 114610.	1.3	36
12	DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 923-928.	1.3	6
13	Importance of Receptor Conformations in Docking Calculation-Based Risk Assessment for Endocrine Disruptors against Estrogen Receptor Î±. ACS Omega, 2019, 4, 6620-6629.	1.6	2
14	Stepwise Mechanism of Temperature-Dependent Coacervation of the Elastin-like Peptide Analogue Dimer, (C(WPGVG)3)2. Biochemistry, 2018, 57, 1582-1590.	1.2	12
15	Angiotensin I Converting Enzyme-inhibiting Peptides Purified from Elastase-degraded Elastin Prepared from Pig Aorta. Current Enzyme Inhibition, 2018, 14, 67-74.	0.3	4
16	Enhancement of Self-Aggregation Properties of Linear Elastin-Derived Short Peptides by Simple Cyclization: Strong Self-Aggregation Properties of Cyclo[FPGVG]_n, Consisting Only of Natural Amino Acids. Biomacromolecules, 2018, 19, 3201-3211.	2.6	10
17	Multifunctional biological activities of water extract of housefly larvae (Musca domestica). PharmaNutrition, 2017, 5, 119-126.	0.8	23
18	Dimerization effects on coacervation property of an elastin-derived synthetic peptide (FPGVG)5. Journal of Peptide Science, 2016, 22, 236-243.	0.8	10

#	Article	IF	Citations
19	Active Sites of Spinoxin, a Potassium Channel Scorpion Toxin, Elucidated by Systematic Alanine Scanning. Biochemistry, 2016, 55, 2927-2935.	1.2	4
20	Role of individual disulfide bridges in the conformation and activity of spinoxin (Î±-KTx6.13), a potassium channel toxin from Heterometrus spinifer scorpion venom. Toxicon, 2016, 122, 31-38.	0.8	1
21	Development of short and highly potent selfâ€assembling elastinâ€derived pentapeptide repeats containing aromatic amino acid residues. Journal of Peptide Science, 2016, 22, 36-42.	0.8	15
22	Design of Phenylalanine-Containing Elastin-Derived Peptides Exhibiting Highly Potent Self-Assembling Capability. Protein and Peptide Letters, 2015, 22, 934-939.	0.4	12
23	Comparison between Coacervation Property and Secondary Structure of Synthetic Peptides, Ile-containing Elastin-derived Pentapeptide Repeats. Protein and Peptide Letters, 2013, 20, 905-910.	0.4	13
24	Fine spatial assembly for construction of the phenol-binding pocket to capture bisphenol A in the human nuclear receptor estrogen-related receptor Â. Journal of Biochemistry, 2012, 151, 403-415.	0.9	14
25	Highly potent binding and inverse agonist activity of bisphenol A derivatives for retinoid-related orphan nuclear receptor RORÎ³. Toxicology Letters, 2012, 212, 205-211.	0.4	9
26	Structural requirements essential for elastin coacervation: favorable spatial arrangements of valine ridges on the threeâ€dimensional structure of elastinâ€derived polypeptide (VPGVG)n. Journal of Peptide Science, 2011, 17, 735-743.	0.8	25
27	Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)14, (Arg/Lys)15]nociceptin on ORL1 receptor binding and activation. Bioorganic and Medicinal Chemistry, 2009, 17, 5683-5687.	1.4	5
28	Spare interactions of highly potent [Arg14,Lys15]nociceptin for cooperative induction of ORL1 receptor activation. Bioorganic and Medicinal Chemistry, 2009, 17, 7904-7908.	1.4	4
29	Exploration of endocrine-disrupting chemicals on estrogen receptor Î± by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-Adamantyl)phenol as a potent endocrine disruptor candidate. Toxicology Letters, 2009, 191, 33-39.	0.4	17
30	Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorganic and Medicinal Chemistry, 2008, 16, 2635-2644.	1.4	16
31	Synergistic effect of basic residues at positions 14â€“15 of nociceptin on binding affinity and receptor activation. Bioorganic and Medicinal Chemistry, 2008, 16, 9261-9267.	1.4	8
32	A Docking Modelling Rationally Predicts Strong Binding of Bisphenol A to Estrogen-Related Receptor γ. Protein and Peptide Letters, 2008, 15, 290-296.	0.4	9
33	Radar Chart Deviation Analysis of Prion Protein Amino Acid Composition Defines Characteristic Structural Abnormalities of the N-Terminal Octapeptide Tandem Repeat. Protein and Peptide Letters, 2008, 15, 949-955.	0.4	1
34	Differential receptor binding characteristics of consecutive phenylalanines in Î¼-opioid specific peptide ligand endomorphin-2. Bioorganic and Medicinal Chemistry, 2007, 15, 3883-3888.	1.4	16
35	cDNA cloning of the housefly pigment-dispersing factor (PDF) precursor protein and its peptide comparison among the insect circadian neuropeptides. Journal of Peptide Science, 2004, 10, 82-91.	0.8	22
36	Molecular cloning and circadian expression profile of insect neuropeptide PDF in black blowfly,Phormia regina. International Journal of Peptide Research and Therapeutics, 2003, 10, 419-430.	0.1	6

#	Article	IF	Citations
37	Site-directed affinity-labeling of delta opioid receptors by SNpys-containing enkephalin and dynorphin analogues. International Journal of Peptide Research and Therapeutics, 2003, 10, 511-522.	0.1	6
38	Molecular cloning and circadian expression profile of insect neuropeptide PDF in black blowfly, Phormia regina. International Journal of Peptide Research and Therapeutics, 2003, 10, 419-430.	0.9	0
39	Site-directed affinity-labeling of delta opioid receptors by. International Journal of Peptide Research and Therapeutics, 2003, 10, 511-522.	0.9	3
40	Aggregation Feature of Fluorine-Substituted Benzene Rings and Intermolecular C-H...F Interaction: Crystal Structure Analyses of Mono- and Trifluoro-L-phenylalanines. Chemical and Pharmaceutical Bulletin, 2003, 51, 1258-1263.	0.6	19
41	Characterization, primary structure and molecular evolution of anticoagulant protein from Agkistrodon actus venom. Toxicon, 2002, 40, 803-813.	0.8	34
42	Structural requirements of nociceptin antagonist Ac-RYYRIK-NH2 for receptor binding. Journal of Peptide Science, 2002, 8, 561-569.	0.8	20
43	Receptor Binding Site of Arg-Lys Triple Repeat in Nociceptin Superagonist. , 2001, , 919-920.		0
44	The Role of Deltorphin II Phenylalanine Residue in Binding to theÎ´Opioid Receptor. Bulletin of the Chemical Society of Japan, 2000, 73, 2549-2552.	2.0	1
45	Exploration of the Role of Phenylalanine in the Thrombin Receptor Tethered-Ligand Peptide by Substitution with a Series of Trifluorophenylalanines. Bulletin of the Chemical Society of Japan, 2000, 73, 2531-2538.	2.0	6
46	Synthesis of a complete set of l-difluorophenylalanines, l-(F2)Phe, as molecular explorers for the CH/Ï€ interaction between peptide ligand and receptor. Tetrahedron Letters, 2000, 41, 923-927.	0.7	22
47	Head-to-Tail Polymerization of Coagulin, a Clottable Protein of the Horseshoe Crab. Journal of Biological Chemistry, 2000, 275, 35297-35301.	1.6	35
48	Highly Potent Nociceptin Analog Containing the Arg-Lys Triple Repeat. Biochemical and Biophysical Research Communications, 2000, 278, 493-498.	1.0	78
49	Structural essentials of xenoestrogen dialkyl phthalates to bind to the estrogen receptors. Toxicology Letters, 2000, 118, 1-8.	0.4	22
50	Exploration of Universal Cysteines in the Binding Sites of Three Opioid Receptor Subtypes by Disulfide-Bonding Affinity Labeling with Chemically Activated Thiol-Containing Dynorphin A Analogs. Journal of Biochemistry, 1999, 126, 254-259.	0.9	12
51	A novel molecular design of thrombin receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1351-1356.	1.0	7
52	Design of serine protease inhibitors with conformation restricted by amino acid side-chain-side-chain CH/? interaction. , 1999, 51, 9-17.		22
53	Effects of Substitution of Hydrophobic Amino Acids by Tryptophan on Receptor Binding and Biological Activity of Neuropeptide Nociceptin. Bulletin of the Chemical Society of Japan, 1999, 72, 1899-1904.	2.0	5
54	X-ray crystal structure of a dipeptide-chymotrypsin complex in an inhibitory interaction. FEBS Journal, 1998, 255, 12-23.	0.2	26

#	Article	IF	Citations
55	The Role of Arginine in Thrombin Receptor Tethered-Ligand Peptide in Intramolecular Receptor Binding and Self-Activation. Bulletin of the Chemical Society of Japan, 1998, 71, 1661-1665.	2.0	9
56	Chymotrypsin inhibitory conformation induced by amino acid side chainâ€“side chain intramolecular CH/Ï€ interaction. Journal of the Chemical Society Perkin Transactions 1, 1996, , 2479-2485.	0.9	22
57	Sensitivity of Opioid Receptor-like Receptor ORL1 for Chemical Modification on Nociceptin, a Naturally Occurring Nociceptive Peptide. Journal of Biological Chemistry, 1996, 271, 23642-23645.	1.6	66
58	Different Roles of Two Consecutive Leucine Residues in a Receptor-Tethered Ligand Peptide (SFLLRNP) in Thrombin Receptor Activation. Bulletin of the Chemical Society of Japan, 1995, 68, 2695-2698.	2.0	8
59	Purification and characterization of a coagulant enzyme, okinaxobin II, from Trimeresurs okinavensis (himehabu snake) venom which releases fibrinopeptides A and B. Toxicon, 1994, 32, 1509-1520.	0.8	11
60	Structural Essentials of Ser-1 in Tethered Peptide Ligand of Human Thrombin Receptor for Phosphoinositide Hydrolysis. Bulletin of the Chemical Society of Japan, 1994, 67, 1659-1663.	2.0	9
61	Chymotrypsin inhibitory conformation of dipeptides constructed by side chain-side chain hydrophobic interactions. Journal of Molecular Recognition, 1993, 6, 95-100.	1.1	7
62	Purification, sequencing and characterization of single amino acid-substituted phospholipase A2 isozymes from Trimeresurus Gramineus (green habu snake) venom. Toxicon, 1993, 31, 957-967.	0.8	28
63	Occurrence of an allosteric transition in the modification of papain withl-1-acetyl-2,3-dihydropyrrolo[2,3-b]-indole-2-carboxamide. Journal of Chromatography A, 1992, 597, 411-413.	1.8	0